Table II.
Main dose combination (for more than 3/4 of the whole treatment time) for apatinib+IE (n=33) and main AEs (according to CTCAE 5.0) for the present retrospective study.
| Apatinib dose | Target AE, n (%) | |||||||
|---|---|---|---|---|---|---|---|---|
| IE dose for combination | 250 mg QD po (BSA >1.0), n=11 | 500 mg QD po or 250 mg QD po (BSA <1.0), n=21 | 375 mg QD po, n=1 | Neutrophil count decreased and thrombocytopenia, grade 4, for >3 days | Bronchial infection, more than grade 3 | Reversible posterior leukoencephalopathy syndrome, grade 3 | Anorexia, grade 3 | Pneumothorax, grade 3 |
| IFO 2.4 g/m2/d d1-5, n=3 | 1 | 2 | 3 (100.0) | 1 (33.3) | ||||
| IFO 2 g/m2/d d1-5, n=1 | 1 | 1 (100.0) | 1 (100.0) | |||||
| IFO 1.8 g/m2/d d1-5, VP16 100 mg/m2/d | 4 | 9 | 1 | 8 (57.1) | 2 (14.3) | 1 (7.1) | 1 (7.1) | |
| d1-5, n=14 | ||||||||
| IFO 1.8 g/m2/d d1-3, VP16 100 mg/m2/d | 4 | 9 | 3 (23.1) | 2 (15.4) | ||||
| d1-3, n=13 | ||||||||
| IFO 1.8 g/m2/d d1-3, n=2 | 1 | 1 | 1 (50.0) | 1 (50.0) | ||||
| Target AE: Neutrophil count decreased and thrombocytopenia, grade 4, for more than 3 day | 4 (36.4%) | 10 (47.6%) | 1 (100.0%) | |||||
| Target AE: Bronchial infection, more than grade 3 | 3 (27.3%) | 3 (14.3%) | ||||||
| Target AE: Reversible posterior leukoencephalopathy syndrome, grade 3 | 1 (4.8%) | |||||||
| Target AE: Anorexia, grade 3 | 1 (4.8%) | |||||||
| Target AE: pneumothorax, grade 3 | 2 (9.5%) | |||||||
AEs, adverse events; BSA, body surface area; CTCAE, Common Terminology Criteria for Adverse Events; IE, ifosfamide and etoposide; IFO, ifosfamide; po, orally; QD, once daily.